You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 廣生堂漲5% 新冠口服藥臨牀試驗獲批 將具備6000萬人份產能
格隆匯 09-26 09:44
格隆匯9月26日丨廣生堂(300436.SZ)漲5.16%,報34.2元,總市值53.26億元。廣生堂25日公吿,公司創新藥控股子公司廣生中霖於9月23日收到國家藥監局下發的關於口服小分子廣譜抗新型冠狀病毒3CL蛋白酶抑制劑一類創新藥物GST-HG171的《藥物臨牀試驗批准通知書》,在新冠藥物的創新研發上取得關鍵里程碑進展。GST-HG171具有廣譜的抗新冠病毒活性,對新冠病毒原始株、奧密克戎BA.4、BA.5變異株以及貝塔、德爾塔變異株均具有高效的病毒抑制活性。目前,除廣生堂將具備6000萬人份的製劑生產,並在未來滿足1億人份的治療需求的產能外,在原料藥方面還將採取全產業鏈統籌的方式,依據自身及國內優秀的中間體和原料藥供應商的立體協同供應和攻關,降低成本保證質量,為國門開放亟需的新冠口服特效藥提供充足的產能支持和保障。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account